Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokines Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Development of secretory leukocyte protease inhibitor (SLPI) variants resistant to degradation by neutrophil elastase Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases Year: 2014
Demonstration of anti-inflammatory properties of an inhaled p38 inhibitor AZD7624 Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4 Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Effect of doxofylline on LPS-induced leukocyte migration to the lung Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
In vitro profile of the new inhaled pan-JAK inhibitor LAS194046Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
AZD9668: Pharmacological characterisation of a novel oral inhibitor of neutrophil elastase (NE) Source: Annual Congress 2010 - Pre-clinical models of airways disease Year: 2010
Decoy chemokine neutraligands with anti-asthmatic activity Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Human Airway Trypsin-like protease exerts potent anti-fibrotic role in vivo. Source: International Congress 2017 – Rare diseases Year: 2017
In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014